Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.